Human cancers are characterized by a high degree of drug resistance. The multidrug resistance transporters MDR1-P-glycoprotein (ABCB1) and ABCC2 (MRP2) are expressed in a variety of human cancers, including hepatocellular carcinoma (HCC). The ABCC2 gene encodes a membrane protein involved in the ATP-dependent transport of conjugates of lipophilic substances. In this study we analyzed the effect of an ABCC2 antisense construct on the chemosensitization of HepG2 cells. Adenoviral vectors were constructed to allow an efficient expression of anti-ABCC2 antisense constructs. The effective target sequence comprised nucleotides 2543-2942 of the human ABCC2 cDNA. Adenoviral delivery of the ABCC2 antisense construct resulted in a reduced IC 50 for doxorubicin (12-fold), vincristine (50-fold), cisplatin (25-fold) and etoposide (VP-16) (25-fold). The adenoviral delivery of the ABCC2 antisense construct was so efficient that chemosensitization of HepG2 cells could even be demonstrated in mass cell cultures without a selection of transduced cells for single ABCC2 antisense-expressing HCC cell clones. After transfection of the ABCC2 antisense-expressing construct, HepG2 cells had significantly reduced ABCC2 mRNA and ABCC2 protein levels. Transduction of the ABCC2 antisense-expressing construct into HepG2 cells resulted in the accumulation of the high-affinity ABCC2 substrate Fluo-3. HepG2 tumors stably transfected with an anti-ABCC2 antisense construct regressed significantly in nude mice upon vincristine treatment. In addition, significant tumor regression was also observed when adenovirus-expressing anti-ABCC2 antisense construct was directly injected into HepG2 tumors in nude mice. Our study demonstrates the specific reversal of ABCC2-related drug resistance in adenovirus-transduced HepG2 cells and in HepG2 tumors in nude mice expressing this ABCC2 antisense construct.
Introduction
Considerable effort has been devoted in recent years to the understanding of the molecular mechanisms underlying the simultaneous resistance of tumor cells to a variety of chemotherapeutic drugs with no structural homology or common cellular target. This pleiotropic drug resistance, termed multidrug resistance (MDR), is a major problem in cancer therapy resulting in the limited efficacy of systemic chemotherapy. The most common mechanism of MDR in cancer cells is the expression of energy-dependent efflux pumps either encoded by the ABCB1 gene (P-glycoprotein (p-gp) MDR1), 1 or the overexpression of ABCC1 (MRP1) or ABCC2 (MRP2). The expression of ABCC1 is associated with extended cross-resistance that overlaps to some extent with that caused by ABCB1. 2 Overexpression of these plasma membrane transport proteins -including ABCC1 and the conjugate export pump ABCC2 can result in the resistance of tumors to various cytotoxic drugs. 3 Northern blot analyses and RNase protection assays have indeed suggested that ABCC2 expression may correlate with MDR. 4 Expression of both human and rat ABCC2 in MDCKII cells confers significant resistance to etoposide and vincristine as well as cisplatin resistance. 3, 4 In contrast, introduction of antisense cDNA reduced the expression of ABCC2 RNA in the human hepatoma cell line HepG2. 5 Human ABCC2 is a polytopic membrane glycoprotein that exports anionic conjugates across the apical membrane of polarized cells. In addition to their role in drug resistance, there is substantial evidence that these efflux pumps have overlapping functions in tissue defense. 6 Inhibitors of ABCC1-or ABCC2-mediated transport of cytotoxic drug complexes or conjugates aim to overcome MDR that is not mediated by ABCB1.
3 ABCC1 and ABCC2 share a similar substrate specificity despite differences in cellular localization and kinetic properties. 3, 7 ABCC2 is localized in the plasma membrane of HepG2 cells and confers drug resistance by exporting drug conjugates or complexes with glutathione.
Many compounds have been shown to reverse the MDR phenotype when coadministered with chemotherapeutic agents to which the cells are resistant. Tsuruo et al. 8 first described MDR reversal by verapamil, a calcium channel blocker, that greatly potentiated the antiproliferative activity of vincristine by its intracellular accumulation in multidrug-resistant P388 murine leukemia cells in vitro and in vivo. However, the innate toxicity of these compounds, for example heart failure, hypotension, hyperbilirubinemia and immunosuppression by cyclosporin A, 9 must be carefully considered. Studies in mutant rats lacking the apical isoform ABCC2 indicate that anionic conjugates of endogenous and exogenous substances cannot exit from cells at a sufficient rate unless an export pump from the MRP family is present in the plasma membrane. Several mutations in the human ABCC2 gene have been identified that result in the absence of the ABCC2 protein from the hepatocyte canalicular membrane and also cause the conjugated hyperbilirubinemia of the Dubin-Johnson syndrome. Human ABCC2 overexpressed in HEK-293 cells enhances the resistance to etoposide (fourfold), cisplatin (10-fold), doxorubicin (7.8-fold) and epirubicin (fivefold). These results clearly demonstrate that ABCC2 confers resistance to several cytotoxic drugs. 3 Less toxic and more potent derivatives need to be developed to overcome drug resistance. Pharmacological strategies aimed at reversing drug resistance include chemical modifications of cytotoxic compounds so that they are no longer P-gp substrates, liposome encapsulation of cytotoxic agents, inhibition of P-gp with antibodies or killing P-gp-expressing tumor cells with immunotoxins, or combinations of these strategies. Another strategy to inhibit P-gp-mediated MDR is the selective block of P-gp expression in cancer cells. This molecular approach should result in the chemosensitization of MDR-gene-expressing cancer cells. Since HepG2 cells are very resistant to chemotherapy, we explored the antisense strategy using cytomegalovirus (CMV) promoter-driven ABCC2 antisense constructs, to restore chemosensitivity of HepG2 cells.
We delivered antisense ABCC2-expressing constructs either by adenoviral transduction and selection for stable antisense-expressing cells. We used high-titer recombinant adenoviruses to deliver and express ABCC2 antisense constructs in HepG2 cells and were able to demonstrate the chemosensitization of HepG2 cells. In addition, we transplanted HepG2 cells stably transfected with antisense ABCC2 into nude mice and challenged them with vincristine to demonstrate a reduction in tumor size. Direct injection of adenovirus-expressing antisense ABCC2 into HepG2 cells that had been transplanted in nude mice also resulted in a significant reduction of tumor growth.
Materials and methods

Materials
The human ABCC2 cDNA and the rabbit polyclonal antibody EAG5 directed against the C-terminal sequence of human ABCC2 were kindly provided by D Keppler (Deutsches Krebsforschungszentrum Heidelberg, Germany). Fluo-3-AM was obtained from Molecular Probes (Eugene, OR, USA).
Cell lines and vectors
Human HepG2 hepatoma cells from American Type Culture Collection (ATCC, Manassass, VA, USA) were used as target cells for the ABCC2-antisense constructs. HepG2 cells were maintained at 371C and 5% CO 2 in RPMI-1640 medium (GIBCO, Heidelberg, Germany) supplemented with 10% heat-inactivated fetal bovine serum (FBS; GIBCO), 5 mM glutamine, penicillin (50 U/ ml) and streptomycin (50 ng/ml). 293 cells, were provided by B Vogelstein (Johns-Hopkins University, Baltimore, MD, USA), were cultured at 371C and 5% CO 2 in complete DMEM medium (GIBCO).
The adenoviral vectors pAdTrack, pAdTrack CMV and wild-type pAdEasy-1, were kindly provided by B Vogelstein (Johns-Hopkins University). pcDNA3.1 þ Zeo, pcDNA 3.1 þ and pcDNA3.1-were obtained from Invitrogen (Groningen, The Netherlands).
Synthesis of ABCC2-antisense constructs and construction of adenoviral vectors
Sense and antisense ABCC2 constructs were designed to bind to regions of the human ABCC2 gene between nucleotides 2543-2942. The human ABCC2 gene was amplified with primers ABCC2 2543 Hind III Forward (aagcttATTGTAGTTCTGGGGAATGGAACAATTGT AGAG) and ABCC2 2942 NotI reverse (gcggccgcTTGC TTGTAGGTACCCCAGGTAGATGGAGA) to yield the ABCC2 antisense fragment and was amplified with primers ABCC2 2543 NotI forward (gcggccgcATTGTAGT TCTGGGGAATGGAACAATTGTAGAG) and ABCC2 2942 HindIII reverse (aagcttTTGCTTGTAGGTACCC CAGGTAGATGGAGA) to yield the sense ABCC2-fragment. These PCR fragments were cloned into the corresponding sites of pAdTrack CMV to yield the sense and antisense ABCC2 expressing vector (pAdTrack CMV-sense ABCC2 and pAdTrack CMV-antisense ABCC2).
Cloning of the sense and antisense ABCC2 fragments into pAd CMV vectors was done the same way as for the GFP-marker protein-expressing pAdTrack CMV vectors to obtain adenoviral plasmids that do not express the GFP protein. The resulting pAd CMV-sense and antisense ABCC2 constructs did not interfere with the fluorescent probe Fluo-3-AM and were used for the Fluo-3-assays.
Sense and antisense ABCC2-expressing recombinant adenoviruses were produced after homologous recombination of antisense-containing pAd Track CMV with wild-type pAdEasy-1 as described. 10 In addition, a control virus was produced the same way containing no for the sense-ABCC2 construct expressed from the CMV promoter. RT-PCRs were carried out in the presence and absence of RT to demonstrate that amplified fragments originated from RNA rather than DNA. Twentyfive cycles were carried out at 2 min at 951C, 2 min at 721C and 1 min at 501C. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were obtained from Clontech.
Drug resistance test in vitro
To detect drug resistance in vitro and therefore cell viability and in vitro cytotoxicity, the WST-1 assay (Roche, Penzberg, Germany) was used as described earlier, 11 using 2 Â 10 6 cells transduced at a MOI of 10 with antisense-expressing or control adenovirus. WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) produces a highly water-soluble and non-cytotoxic formazan dye, that allows each assay to be carried out in culture dishes. Cells were seeded in quadruplicates in 96-well culture plates at a density of 1 Â 10 5 cells per well 24 h after infection. Twenty-four hours later vincristine, doxorubicin, VP-16 or cisplatin were added at various concentrations and incubation continued for 4 days. Plates were read in a Bio-Rad microplate reader (Hercules, CA, USA) at 550 nm. The relative drug resistance was determined by comparing the IC 50 values of transduced and nontransduced cells. IC 50 was defined as the concentration of cytotoxic drug causing 50% inhibition of cell growth, as compared to the untreated control. IC 50 values were calculated by loglinear interpolation of data points.
Detection of ABCC2 expression by northern blot analysis Northern blot analyses were performed by standard techniques. 12 The full-length ABCC2 cDNA labeled with [g-32 P]dCTP was used as the hybridization probe. A g-actin probe was used as an internal standard. ABCC2 expression was semi-quantitatively determined by densitometry of the autoradiograms. Levels were expressed as arbitrary expression units (AEU) by assigning the value of 1 AEU to the signal obtained for untransduced HepG2 cells.
Fluo-3 assay
HepG2 cells were analyzed when maximal density and polarity was reached, typically after 7-10 days in culture. At this time, 70-80% of cells formed intercellular phaseluscent spherical structures ('apical vacuoles') corresponding to bile canalicular-like spaces as described. 13 Fluo-3-AM, which enters the tubular cells by diffusion, is hydrolyzed intracellularly into the fluorescent anion Fluo-3. Fluo-3 is a dye that is transported by ABCC2 and a variety of other transporters located in the cell membrane. Fluo-3-AM was dissolved in dimethylsulfoxide to give a stock solution of about 0.5 mmol/l. The exact concentration of the stock solution was determined by measurement of the absorbance at 464 nm of a 1:200 dilution in methanol using a molar extinction coefficient of 26 cm 2 /mmol. About 1.5 Â 10 6 HepG2 cells grown in each well of a six-well plate were infected at a MOI of 10 with sense and antisense ABCC2-expressing recombinant adenoviruses. After 24 h, cells were incubated for 15 min with 1 mmol/l Fluo-3-AM, washed once with phosphate-buffered saline (PBS), and observed over 15 min by phase-contrast and epifluorescence optics on a Zeiss Axioskop (Carl Zeiss, Jena, Germany) using a Â 40 magnification. Fluorescent apical vacuoles were counted and expressed as a percentage of the total number of apical vacuoles seen by phase contrast.
Detection of ABCC2 and ABCB1 expression by western blot analysis Western blot analyses were carried out as described. 2, 14 HCC models in nude mice and treatment of the tumor Groups of six adult (7-week-old) athymic nude mice (Sprague-Dawley, Oncotest, Freiburg, Germany) were The ability of pAdTrack CMV-antisense ABCC2 to suppress tumor growth in vivo was analyzed as follows: tumor foci were established by injecting 1 Â 10 7 HepG2 cells into athymic nude mice (Sprague-Dawley). In brief, the cells were suspended in 100 ml of saline and injected s.c. into the flank. Six days after the injection of HepG2 cells, 1 Â 10 9 PFUs of adenoviral vectors in a total volume of 100 ml of dialysis buffer were directly injected into the growing tumor from three directions for 2 successive days. The needles were retracted over 10 s. The following day and on days 7 and 21 after adenoviral injection of 0.6 mg/kg of vincristine or 0.9% NaCl solution were administered into the tail vein. Intravenously administered volumes were identical. The tumor size was measured with calipers in three dimensions. Tumor size is presented as the mean relative tumor volume 7s.d. (%).
Statistical analysis
Statistical analysis was performed using the MannWhitney U-test and StatView software (Abacus Concepts Inc., Berkeley, CA, USA). A Po0.05 was considered to be statistically significant.
Results
Establishment of multidrug-resistant sense and antisense ABCC2-expressing HepG2 cells To achieve a high transduction efficiency of HepG2 cells we chose recombinant adenoviruses to deliver sense and antisense ABCC2 constructs, because they can be grown to a high titer and are known to be able to transduce HepG2 cells. Sense and antisense ABCC2-expressing adenoviruses as well as a control adenovirus expressing no gene of interest as a negative control virus had titers of upto almost 10 10 colony-forming units (CFU)/ml. The efficacy of antisense ABCC2 constructs after adenoviral delivery was compared to stably anti-ABCC2 antisenseexpressing HepG2 transfectants. Northern and western blot analysis of ABCC2 and ABCB1 expression levels Levels of ABCC2 mRNA were analyzed by northern blot and ABCC2 protein levels by western blot analysis. For northern blot analysis, 10 mg of total RNA obtained from HepG2 cells that had been transduced at a MOI of 10 by adenovirus were used. ABCC2 mRNA was detectable in HepG2 cells, control-infected and in cells infected with sense ABCC2 expressing adenovirus. In contrast, ABCC2-expression was less than 5% of normal level in HepG2 cells infected with an anti-ABCC2 antisenseexpressing adenovirus (Figure 2) . No decrease in ABCB1 mRNA levels was observed in HepG2 cells infected with an adenovirus expressing the antisense ABCC2 construct demonstrating the specificity of the antisense ABCC2 construct. b-Actin levels were also unchanged in these cells. HepG2 cells that had been infected at a MOI of 10 by an adenovirus expressing the antisense ABCC2 construct had significantly lower ABCC2 protein levels 
Drug resistance profiles of adenovirus-transduced ABCC2-antisense-expressing HepG2 cells in vitro
HepG2 cells demonstrated an IC 50 for vincristin of 0.24 and of 0.5 mM for doxorubicin, 6 mM for VP-16 and 1.5 mM for cisplatin infected by a control adenovirus ( Figure 5 ). This was similar to HepG2 cells infected with adenovirus expressing the sense ABCC2 construct. Following transduction with an antisense ABCC2-expressing adenovirus driven by a CMV promoter the IC 50 decreased to 0.04 mM for vincristine, 0.05 mM for doxorubicin, 0.5 mM for VP-16 and 0.24 mM for cisplatin ( Figure 5 ). Taken together, these findings demonstrate a significant chemosensitization of HepG2 cells after adenoviral delivery of antisense ABCC2 constructs driven by a CMV promoter. Stably transfected HepG2 cells that expressed a sense or an antisense ABCC2 construct under the control of a CMV promoter (pcDNA3.1 þ /antisense-ABCC2 or pcDNA3.1 þ /sense-ABCC2) were unchanged in morphology and growth rate after selection by G418 (data not shown). Forty-eight clones were selected with G418, which stably expressed the antisense-ABCC2 construct. Clone A was representative for three clones, which most efficiently reversed the ABCC2 phenotype. Clone B was representative of 20 clones, clone C was representative of When an adenoviral vector expressing antisense ABCC2 was directly injected into pre-established tumors of HepG2 cells, tumor cell growth in each treatment group was similarly reduced after vincristine treatment. In ). Statistical significance between the mean value on days 10 and 20 was observed at Po0.05.
Discussion
The identification of specific inhibitors of MRP1-and ABCC2-mediated transport is central for strategies aimed at reversing MDR. Some ATP-dependent export pumps are strongly expressed in apical membrane domains of polarized cells. In the canalicular membrane of hepatocytes, for example ATP-dependent primary-active export Anti-ABCC2 antisense constructs Y Folmer et al pumps for bile salts, hydrophobic cytotoxic drugs as well as glutathione conjugates and glucuronides can be found. Some of these transport proteins are also expressed in plasma membranes of tumor cells and may lead, when overexpressed, to MDR. 3 Studies using human and canine cells stably transfected with ABCC2 have demonstrated that overexpression of ABCC2 results in drug resistance to various cytotoxic drugs, for example cisplatin, etoposide, doxorubicin and epirubicin. 3 HCC is one of the most common cancers, causing an estimated 1 250 000 deaths per year worldwide with no effective chemotherapy available. HCC chemoresistance has been attributed to ABCB1 overexpression. 14, 15 Antisense oligonucleotides have been shown to modulate ABCB1-mediated MDR in tumor cells. 16 Hammerhead ribozymes restored the chemosensitivity of MDR-expressing cells. 17 Stable transfectants generated using retroviral vectors that expressed ABCB1 ribozymes resulted in significantly decreased ABCB1 mRNA levels. 18 Reversal of cisplatin resistance by anti-ABCC2 hammerhead ribozymes was demonstrated in human cancer cells. 19 The expression of ABCC2 was specifically reduced by antisense DNA expressed from a CMV expression A 'multitarget multiribozyme' constructed that consisted of three hammerhead motifs directed against transcripts of ABCB1, BCRP and ABCC2 specifically reduced the corresponding transporter ABCB1, BCRP and ABCC2 in all cellular systems. 21 Interestingly, it was shown that bile acid-modified oligodeoxynucleotides are secreted via ABCC2 into bile. Oligodeoxynucleotide secretion was radically diminished in a mutant Wistar rats lacking a functional ABCC2. 22 Adenoviral delivery of herpes simplex virus type-1 (HSV) thymidine kinase (TK) and other genes to HepG2 cells in vitro and in preclinical HCC animal models in vivo has been well documented. 23, 24 Adenoviral vectors are highly efficient for in vitro and in vivo gene transfer into a variety of tissues and tumors and they are used in about 20% of all clinical gene therapy trials adenoviral delivery is used.
Genetically engineered tumor-targeted replication-competent E1B-deleted adenoviruses will only replicate in cells that lack functional p53 gene and will therefore kill these tumor cells specifically. In an in vivo study, this mutant adenovirus ONYX-015 has been shown to kill cervical carcinoma cells lacking functional p53. 25 High adenoviral transduction efficiency is necessary to prevent the survival of non-transduced cancer cells. Recently, it was demonstrated that a recombinant adenovirus carrying the whole human ABCB1-cDNA sequence in reverse orientation could be packaged and introduced to HepG2 cells. 26 Our study demonstrates the efficient adenoviral transfer of the ABCC2 gene into HepG2 cells and the efficacy of anti-ABCC2 antisense constructs after adenoviral delivery. Stable antisense-ABCC2-expressing transfectants displayed a markedly reduced resistance to vincristine, VP-16, doxorubicin and cisplatin compared to the parental cell line. The level of expression of antisense-ABCC2 in different clones correlated with the resistance level to chemotherapeutic compounds analyzed.
ABCC2 transports anionic conjugates and certain amphiphilic anions across the apical membrane of polarized cells Hep G2 human hepatoma cells retain hepatic polarity and form apical vacuoles into which cholephilic substances are secreted. Cantz et al. 27 demonstrated that human ABCC2 is expressed in the apical vacuole membrane of polarized Hep G2 cells and that Fluo 3 secretion into the apical vacuoles was inhibited by ABCC2 antisense expression. This assay can therefore be used to analyze the function of human ABCC2 and the action of inhibitors based on the secretion of Fluo 3. In this context, we were able to show directly that Fluo 3 secretion is significantly decreased after infection of HepG2 cells with an antisense ABCC2-expressing adenovirus. Here we could demonstrate, to our knowledge for the first time, that tumor of subcutaneously grown hepatoma cells overexpressing ABCC2 protein regressed in size upon antisense ABCC2 expression in combination with chemotherapy due to chemosensitization. Tumor size regression was also observed when adenovirus expressing antisense ABCC2 was directly injected into HepG2 tumors in nude mice. These observations could now be extended and be evaluated in a preclinical mouse model.
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